Skip to main content
Company profile
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc.

Pipeline2 assets

  • BarzolvolimabCDX-0159 / KIT / KIT antagonist mAb / Immunology/inflammation
    Chronic spontaneous urticariaPhase 3ongoingCold urticariaPhase 3ongoingSymptomatic dermographismPhase 3ongoing
  • CDX-622CDX-622 / TSLP; SCF / Bispecific antibody / Immunology/inflammation
    Healthy volunteersPhase 1ongoingAsthma proof of mechanismPhase 1ongoing

Latest news9 items

All news

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab’s potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups Clinically meaningful and

Trial Results • Phase 3Topline results Tue, Sep 22, 2026, 8:00 AM ET

Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET. The webcast of the presentation will be available on the “ Events and

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/ Oct 2026; BLA submission planned for 2027 Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling; Phase 2 topline data

Presentation / Abstract • Phase 3EAACI presentation Mon, Jun 1, 2026

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen Profound systemic mast cell depletion, as evidenced by significant reduction in serum tryptase, observed Phase 3 CSU topline data

Trial Results • Phase 2Phase 2 topline results Tue, Jul 21, 2026

Celldex Announces Planned Transition of Chief Financial Officer

HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company’s Chief Financial Officer since 2017 and as a

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free

Presentation / Abstract • Phase 2EAACI presentation Sun, Jun 14, 2026

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functions Rapid,

Presentation / Abstract • Phase 1EAACI presentation Sun, Jun 14, 2026

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared

Presentation / Abstract • Phase 1EAACI poster session Sun, Jun 14, 2026, 5:15 AM ET

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD)

Enrollment • Phase 3
Celldex Therapeutics, Inc. • Endpoint Arena